Navigation Links
Physicians' Adoption of Velcade for the Treatment of Chronic Graft Versus Host Disease Will Drive Growth In This Market Through 2021
Date:2/13/2013

BURLINGTON, Mass., Feb. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that physicians' adoption of Millennium (Takeda)/Johnson & Johnson's Velcade for the treatment of chronic graft versus host disease (GVHD) following the publication of results from studies sponsored by prominent oncology research centers will drive growth in the GVHD market through 2021. In particular, Velcade's uptake in the first-line treatment setting will displace lower-priced standards of care such as corticosteroids and small-molecule immunosuppressants.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

According to Niche Markets and Rare Diseases: Graft Versus Host Disease, expert physicians report that Velcade's market potential could be even greater, based on their interest in employing Velcade in the prophylactic setting. The market opportunity for prophylactic therapies, based on underlying population sizes, is up to three times larger than for primary or later-line treatments, and although Velcade is unlikely to secure regulatory approval for GVHD, the substantial need for more-effective treatments will drive uptake.

The report also finds that although the current clinical pipeline is sparse, several drug developers have nevertheless been drawn into GVHD drug development by the potential to secure orphan-drug designation for novel agents.

"GVHD is an excellent illustration of the orphan drug designation working effectively — without the benefits of the orphan designation, companies might be reluctant to develop drugs for such a small, specific population," said Decision Resources Senior Vice President Cynthia Mundy , Ph.D.

GVHD is a relatively rare condition that occurs in a patient population — severely ill oncology patients eligible for hematopoietic stem cell transplant — who already have access to costly specialized treatment. Interviewed hematologist/oncologists report that cost concerns have little to no impact on current treatment decisions, and do not anticipate major changes in payers' attitudes toward GVHD reimbursement following launches of novel therapies.

About Graft Versus Host Disease
Graft Versus Host Disease is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
2. Sunshine Act Survey: More Than 50% of Physicians Unprepared
3. iPad Altering Interaction between Pharma Sales Forces, Physicians, & Consumers
4. Harris Poll Study Links Emotional Connection to Physicians Trust in Pharmaceutical Products
5. Kerry R. Hicks Joins Physicians Capital Investments as Vice-Chairman of Board
6. Survey of Oncologists Reveals 98.9% of Physicians Experienced Cancer Drug Shortages in Last 12 Months
7. Free Webinar Helps Physicians and Pharmacists Learn How to ePrescribe Controlled Substances
8. PhysiciansNews.com and UBM Medica US Announce Comprehensive Marketing and Distribution Partnership
9. South Korean lawmakers one step from rigorous new system for stem cell Advancement: scientists, physicians and patients applaud, urge lawmakers to complete The Job
10. Mt. Airy Hospital Selects Sound Physicians - Leading Hospitalist Organization Focuses on Improving Quality and Reducing Cost of Inpatient Care
11. iPads Transforming How Pharma Sales Forces Interact with Physicians & Payers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb 24, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
Breaking Medicine News(10 mins):